The current focus of the Biomanufacturing platform is the rapid development of biopharmaceutical production processes that provide protein, cell and gene therapeutics, and vaccines. This includes upstream- and downstream processing, formulation, and fill & finish.
Members / People
The platform is led by Prof. Regine Eibl and Prof. Dr. Thomas Villiger. It has both industrial and academic research partners in Switzerland, Europe and the USA and closely cooperates with the DECHEMA working group “Single-use technology in biopharmaceutical manufacturing”. Participating Biotechnet research groups are listed on the right.
Join the platform
To join the platform, please contact Thomas Villiger or Regine Eibl.
In 2011, the Single-Use Technology platform, the predecessor of the Biomanufacturing platform, was founded. The goal was to support manufacturers and users of single-use systems with the development and implementation of these technologies in biopharmaceutical production processes. Single-use technology in biomanufacturing is now well established in R&D, pre- and clinical production, and commercial processes. Hybrid production facilities, which combine reusable and single-use systems, have steadily become omnipresent in Switzerland and beyond. With increasing complexity of biopharmaceuticals, higher cost pressures, tighter control of product quality, and more stringent regulatory requirements, the scope of the platform was expanded from “Single-use Technology” to “Biomanufacturing” in November 2022. This shall provide an end-to-end environment for biopharmaceutical development and manufacturing. Current topics of interest include intensified and continuous production processes that guarantee target product quantities in a shorter time, larger product quantities in a comparable time, higher space time yields or advanced process control using state-of-the-art sensors.